期刊文献+

肾素抑制剂阿利吉仑 被引量:5

Direct renin inhibition:Aliskiren
原文传递
导出
摘要 阿利吉仑(aliskiren)用于肾素-血管紧张素-醛固酮系统(RAAS)的起始步骤达到降压目的,其半衰期极长,耐受性可与安慰剂相媲美。单用阿利吉仑的降压疗效与其他一线降压药相似,甚至更优;联合用药疗效明显提高,不发生有害的药物间相互作用。对于特殊高血压人群如合并糖尿病、肥胖、或是老年高血压病人,阿利吉仑也表现出极好的疗效和耐受性。阿利吉仑对靶器官起到明显的保护作用,可逆转和延缓高血压引起的心血管和肾脏损害。 Aliskiren is an effective antihypertensive drug by inhibiting the renin-angiotensin system.It has a prolonged duration of action and favorable tolerability comparable with placebo.The blood pressure-lowering effect of aliskiren monotherapy is similar,if not superior,to that of other first-line antihypertensive agents,and is greatly enhanced when aliskiren is combined with various other antihypertensive medications,without any adverse drug interactions.Aliskiren is also an effective and well tolerated therapy in special populations,including diabetic,obese,and elderly hypertensives.Beyond its blood pressure-lowering efficacy,aliskiren has positive effects on markers of cardiovascular and renal damage.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第3期221-224,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家"重大新药创制"科技重大专项子项目基金资助项目(2009ZX09501-032)
关键词 肾素抑制剂 阿利吉仑 高血压 renin inhibitors aliskiren hypertension
  • 相关文献

参考文献24

  • 1Rashid H.Direct renin inhibition:an evaluation of the safety andtolerability of aliskiren[J].Curr Med Res Opin,2008;24:2627-2637.
  • 2Waldmeier F,Glaenzel U,Wirz B,et al.Absorption,distributionmetabolism and elimination of the direct renin inhibitor aliskiren inhealthy volunteers[J].Drug Metab Disposit Fast Forward,2007;35:1418-1428.
  • 3Zhao C,Vaidyanathan S,Yeh CM,et al.Aliskiren exhibits similapharmacokinetics in healthy volunteers and patients with type 2 dia-bete mellitus[J].Clin Pharmacokinet,2006;45:1125-1134.
  • 4Vaidyanathan S,Bartlett M,Dieterich HA,et al.Pharmacokineticinteraction of the direct rennin inhibitor aliskiren with furosemideand extended-release isosorbide-5-monoitrate in healthy sub-jects[J].J Clin Pharmacol,2008;48:1323-1338.
  • 5Tapaninen T,Neuvonen PJ,Niemi M.Rifampicin reduces the plas-ma concentration and the rennin-inhibiting effect of aliskiren[J].Eur J Clin Pharmacol,2010;66:497-502.
  • 6Gradman AH,Kad R.Renin inhibition in hypertension[J].J AmColl Cardiof,2008;51:519-528.
  • 7Duncan J,Campbell.Interpretation of plasma renin concentration inpatients receiving aliskiren therapy[J].Hypertension,2008;51:15-18.
  • 8Schmieder RE,Philipp T,Guerediaga J,et al.Long-tern antihy-pertensive efficacy and safety of the oral direct rennin inhibitoraliskiren:a 12-month randomaized,double-blind comparator tri-al with hydrochlorothiazide[J].Circulation,2009;119:417-425.
  • 9Ayalasomayajula S,Tchaloyan S,Yeh CM,et al.Efficacy andsafety of the direct rennin inhibitor aliskiren and ramipril alone or incombination in patients with diabetes and hypertension[J].J ReninAngiotensin Aldosterone Syst,2007;8:190-198.
  • 10Blumenstein M,Romaszko J,Caldern A,et al.Antihypertensiveefficacy and tolerability of aliskiren/hydrochlorothiazide(HCT)sin-gle-pill combination in patients who are non-responsive to HCT25mg alone[J].Curr Med Res Opin,2009;25:903-910.

同被引文献45

  • 1守山敏樹,张川.代谢综合征与慢性肾脏病[J].日本医学介绍,2007,28(7):309-312. 被引量:3
  • 2Kelly DJ,Zhang Y, Moe G, et al.Aliskiren, a novel rennin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats[J]. Diabetologia, 2007,50 ( 12 ) : 2398-2404.
  • 3Krum H, Schlaich M, Whitbourn R, et al.Catheter-based renal sympa thetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study [J].Lancet, 2009,373 (9671): 1275- 1281.
  • 4Schmieder RE, Redon J, Grassi G, et al. 2012 ESH Position Paper:. Renal denervation-an interventional therapy of resistant hypertension[J]. Journal of Hypertension, 2012,30 (5) : 837-841.
  • 5Zhu JR, Sun NL, Yang K, et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension [ J ]. Hypertens Res,2012,35 ( 1 ) :28 - 33.
  • 6Morgado MP, Rolo SA, Castelo - Branco M, et al. Efficacy of de eombirtatiort for the treatment of hypertension : A meta - analytical approach [ J ]. Open Cardiovasc Med J,2011,5(1) :6 -14.
  • 7Huang ML, Li X, Meng Y, et al. Upregulation of angiotensin - converting enzyme(ACE) 2 in hepatic fibrosis by ACE inhibitors [ J]. Clin Exp Pharm Phy,2010,37 (1) :el -e6.
  • 8Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis [ J ]. Nature Review Nephrology, 2013,9 (8) :459 -469.
  • 9Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy [ J ]. J Hypertens,2013,31 (10) :2085 - 2093.
  • 10Bertagna X, Pivonello R, F|eseriu M, et al. LCI699, a potent 1113 - hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: Results from a muhicenter, proof- of- concept study [ J ]. J Clin Endocrinol Metabol, 2014,99 ( 4 ) : 1375 - 1383.

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部